These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10752599)

  • 1. The initial treatment of Parkinson's disease.
    Factor SA
    Mov Disord; 2000 Mar; 15(2):360-1. PubMed ID: 10752599
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL
    Mov Disord; 2000 Mar; 15(2):361-2. PubMed ID: 10752600
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuncts to levodopa therapy: dopamine agonists.
    Poewe W
    Neurology; 1998 Jun; 50(6 Suppl 6):S23-6; discussion S44-8. PubMed ID: 9633683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 5. Initial drug treatment in Parkinson's disease.
    Muzerengi S; Clarke CE
    BMJ; 2015 Sep; 351():h4669. PubMed ID: 26385603
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 11. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
    Nutt JG; Obeso JA; Stocchi F
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S109-15. PubMed ID: 11052228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
    Arnold G; Kupsch A
    Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review on initial drug treatment in Parkinson's disease did not mention entacapone.
    Elrington GM
    BMJ; 2015 Nov; 351():h5843. PubMed ID: 26530214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.